CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Avigen, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Avigen, Inc.
1301 Harbor Bay Parkway
Phone: (510) 748-7150p:510 748-7150 Alameda, CA  94502  United States Ticker: AVGN AVGN

This company was Merged or Acquired on 12/18/2009.
This company ceased filing statements with the SEC on 12/18/2009.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Avigen, Inc. is a biopharmaceutical company that has focused on identifying and developing differentiated products to treat patients with serious disorders. The Company’s potential product is AV411, a glial attenuator, for neuropathic pain and opioid withdrawal and methamphetamine addiction. The Company is a development-stage company. Prior to October 2008, it had been developing a product candidate, AV650, for the treatment of spasticity associated with multiple sclerosis. In December 2008, it completed a sale of its early-stage AV513 program to Baxter Healthcare Corporation. In December 2009, MediciNova, Inc. completed its acquisition of the Company.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/200912/31/2008YesYes---

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Zola P.Horovitz 74 2/23/2006 11/1/1994
President, Chief Executive Officer,Chief Financial Officer Andrew A.Sauter 42 3/26/2009 1/31/2006
Vice President - Research & Development, Corporate Secretary Kirk W.Johnson 49 3/26/2009 6/1/2004
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 4 (As of 3/31/2009)
Outstanding Shares: 29,836,365 (As of 10/30/2009)
Shareholders: 104
Stock Exchange: NASD
Federal Tax Id: 133647113
Fax Number: (510) 748-7155
Email Address: paulson@avigen.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023